UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Advances in lung cancer diagnosis and treatment - a review

Laeknabladid, 2022-01, Vol.108 (1), p.17-29

2022

Volltextzugriff (PDF)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma

Cancer management and research, 2015-01, Vol.7 (default), p.65-73

2015

Volltextzugriff (PDF)

The Nobel prize in Medicine 2018 - A revolution in cancer management

Laeknabladid, 2018-11, Vol.104 (11), p.489-489

Gunnarsson, Orvar

2018

Volltextzugriff (PDF)

Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake

JAMA : the journal of the American Medical Association, 2005-11, Vol.294 (18), p.2336

2005

Volltextzugriff (PDF)

Vitamin D status and skeletal health in black men starting androgen deprivation therapy for prostate cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e15139-e15139

2012

Volltextzugriff (PDF)

The challenge of implementing Less is More medicine: A European perspective

European journal of internal medicine, 2020-06, Vol.76, p.1-7

2020

Volltextzugriff (PDF)

Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT214-CT214

2020

Volltextzugriff (PDF)

Abstract C100: Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.C100-C100

2019

Volltextzugriff (PDF)

Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.398-398

2015

Volltextzugriff (PDF)

Bylting í meðferð krabbameina

Laeknabladid, 2018-11, Vol.2018 (11), p.489-489

Gunnarsson, Örvar

2018

Volltextzugriff (PDF)

HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.4543-4543

2015

Volltextzugriff (PDF)

Abstract CT340: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC): results from the planned interim analysis

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT340-CT340

2014

Volltextzugriff (PDF)

Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy

Cancers, 2015-04, Vol.7 (2), p.679-687

2015

Volltextzugriff (PDF)

HIF inhibition in mRCC: Planned interim analysis of CRLX101 with bevacizumab (bev), a phase 1b/2a

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e15611-e15611

2014

Volltextzugriff (PDF)

Risk-stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors

Clinical genitourinary cancer, 2016-12, Vol.14 (6), p.524-529

2016

Volltextzugriff (PDF)

Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2014-02, Vol.32 (4_suppl), p.412-412

2014

Volltextzugriff (PDF)

Afdrif þeirra sem gengist hafa undir æxlisminnkandi skurðaðgerð og hitaða lyfjameðferð innan lífhimnu

Laeknabladid, 2020-07, Vol.2020 (708), p.344-348

2020

Volltextzugriff (PDF)

Yellow nail syndrome

Laeknabladid, 2007-11, Vol.93 (11), p.751-753

2007

Volltextzugriff (PDF)

Case of the month. Pulmonary Aspergilloma

Laeknabladid, 2008-02, Vol.94 (2), p.162-162

2008

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(20)

Sprache

Englisch
(17)
Isländisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(7)
Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Male
(4)
Middle Aged
(4)
Oncology
(4)
Adult
(3)
Aged
(3)
General & Internal Medicine
(3)
Medicine, General & Internal
(3)
Aged, 80 And Over
(2)
Female
(2)
Iceland - Epidemiology
(2)
Treatment Outcome
(2)
Young Adult
(2)
Adolescent
(1)
Adrenal Cortex Hormones - Therapeutic Use
(1)
Androgen Deprivation Therapy
(1)
Androgens
(1)
Antineoplastic Combined Chemotherapy Protocols - Administration & Dosage
(1)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(18)
Publisher or Other Site
(9)
MEDLINE
(7)
Journals@Ovid Full Text
(7)
IngentaConnect Journals
(3)
IngentaConnect Journals
(2)
Elsevier ScienceDirect Journals Complete
(1)
Taylor & Francis Journals
(1)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Advances in lung cancer diagnosis and treatment - a review

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma

The Nobel prize in Medicine 2018 - A revolution in cancer management

Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake

Common and Rare Sequence Variants Influencing Tumor Biomarkers in Blood

Vitamin D status and skeletal health in black men starting androgen deprivation therapy for prostate cancer

The challenge of implementing Less is More medicine: A European perspective

Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC

Abstract C100: Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)

Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy

Bylting í meðferð krabbameina

HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev)

Abstract CT340: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC): results from the planned interim analysis

Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy

HIF inhibition in mRCC: Planned interim analysis of CRLX101 with bevacizumab (bev), a phase 1b/2a

Risk-stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors

Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC)

Afdrif þeirra sem gengist hafa undir æxlisminnkandi skurðaðgerð og hitaða lyfjameðferð innan lífhimnu

Yellow nail syndrome

Case of the month. Pulmonary Aspergilloma

Suchergebnisse filtern